Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus multilocularis | cyclins | 0.0021 | 0.2597 | 0.2597 |
Brugia malayi | Cyclin, N-terminal domain containing protein | 0.0021 | 0.2597 | 0.2597 |
Echinococcus granulosus | cyclins | 0.0021 | 0.2597 | 0.2597 |
Echinococcus multilocularis | cyclin b3 | 0.0021 | 0.2597 | 0.2597 |
Schistosoma mansoni | cyclins | 0.0021 | 0.2597 | 1 |
Entamoeba histolytica | ras-1, putative | 0.0065 | 1 | 1 |
Echinococcus multilocularis | cyclins | 0.0021 | 0.2597 | 0.2597 |
Leishmania major | CYC2-like cyclin, putative,cyclin 6, putative | 0.0021 | 0.2597 | 0.5 |
Brugia malayi | Cyclin, N-terminal domain containing protein | 0.0021 | 0.2597 | 0.2597 |
Brugia malayi | Ras-related protein R-Ras2 | 0.0065 | 1 | 1 |
Echinococcus granulosus | cyclins | 0.0021 | 0.2597 | 0.2597 |
Schistosoma mansoni | cyclin B | 0.0021 | 0.2597 | 1 |
Echinococcus multilocularis | G2:mitotic specific cyclin B3 | 0.0021 | 0.2597 | 0.2597 |
Echinococcus multilocularis | ras gtpase | 0.0065 | 1 | 1 |
Loa Loa (eye worm) | Ras protein let-60 | 0.0065 | 1 | 1 |
Trichomonas vaginalis | rheb, putative | 0.0065 | 1 | 1 |
Entamoeba histolytica | Ras family GTPase | 0.0065 | 1 | 1 |
Echinococcus granulosus | cyclins | 0.0021 | 0.2597 | 0.2597 |
Brugia malayi | Cyclin, N-terminal domain containing protein | 0.0021 | 0.2597 | 0.2597 |
Loa Loa (eye worm) | hypothetical protein | 0.0065 | 1 | 1 |
Giardia lamblia | Cyclin A | 0.0021 | 0.2597 | 0.5 |
Echinococcus granulosus | G2:mitotic specific cyclin B3 | 0.0021 | 0.2597 | 0.2597 |
Trichomonas vaginalis | ral, putative | 0.0065 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0021 | 0.2597 | 0.2597 |
Trypanosoma cruzi | CYC2-like cyclin, putative | 0.0021 | 0.2597 | 0.5 |
Echinococcus granulosus | ras gtpase | 0.0065 | 1 | 1 |
Echinococcus multilocularis | cyclins | 0.0021 | 0.2597 | 0.2597 |
Trichomonas vaginalis | ras-dva small GTPase, putative | 0.0065 | 1 | 1 |
Trichomonas vaginalis | rap1 and, putative | 0.0065 | 1 | 1 |
Echinococcus granulosus | cyclin B3 1 | 0.0021 | 0.2597 | 0.2597 |
Echinococcus granulosus | cyclin B | 0.0021 | 0.2597 | 0.2597 |
Leishmania major | cyclin | 0.0021 | 0.2597 | 0.5 |
Trypanosoma brucei | mitotic cyclin 6 | 0.0021 | 0.2597 | 0.5 |
Trichomonas vaginalis | dexras1, putative | 0.0065 | 1 | 1 |
Echinococcus multilocularis | cyclins | 0.0021 | 0.2597 | 0.2597 |
Trypanosoma cruzi | cyclin, putative | 0.0021 | 0.2597 | 0.5 |
Echinococcus multilocularis | cyclins | 0.0021 | 0.2597 | 0.2597 |
Echinococcus multilocularis | cyclins | 0.0021 | 0.2597 | 0.2597 |
Trypanosoma cruzi | cyclin, putative | 0.0021 | 0.2597 | 0.5 |
Plasmodium falciparum | cyclin | 0.0021 | 0.2597 | 0.5 |
Onchocerca volvulus | 0.0021 | 0.2597 | 1 | |
Trichomonas vaginalis | GTP-binding protein rit, putative | 0.0065 | 1 | 1 |
Loa Loa (eye worm) | cyclin domain-containing protein | 0.0021 | 0.2597 | 0.2597 |
Echinococcus multilocularis | cyclin B | 0.0021 | 0.2597 | 0.2597 |
Echinococcus granulosus | cyclins | 0.0021 | 0.2597 | 0.2597 |
Giardia lamblia | Hypothetical protein | 0.0021 | 0.2597 | 0.5 |
Echinococcus granulosus | cyclin b3 | 0.0021 | 0.2597 | 0.2597 |
Trypanosoma cruzi | cyclin 6, putative | 0.0021 | 0.2597 | 0.5 |
Echinococcus multilocularis | cyclin B3 1 | 0.0021 | 0.2597 | 0.2597 |
Loa Loa (eye worm) | hypothetical protein | 0.0021 | 0.2597 | 0.2597 |
Schistosoma mansoni | cyclin B3 | 0.0021 | 0.2597 | 1 |
Echinococcus granulosus | cyclins | 0.0021 | 0.2597 | 0.2597 |
Echinococcus multilocularis | cyclins | 0.0021 | 0.2597 | 0.2597 |
Toxoplasma gondii | hypothetical protein | 0.0016 | 0.1744 | 0.5 |
Entamoeba histolytica | Ras family GTPase | 0.0065 | 1 | 1 |
Giardia lamblia | G2/mitotic-specific cyclin B | 0.0021 | 0.2597 | 0.5 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.